3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Advanced Malignancies
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Solid Tumors, KRAS Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Opioid-Related Disorders
1
Lung Neoplasms
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Leiomyosarcoma
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Hematologic Neoplasms
1
Healthy Adult Participants
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Cancer Pain
1
Interventions
Doxorubicin
7
pembrolizumab
5
Radiotherapy
5
Specimen Handling
4
Radiation
4
Magnetic Resonance Spectroscopy
4
palbociclib
3
eribulin
3
Ifosfamide
3
Biopsy
3
pazopanib
2
brigimadlin
2
abemaciclib
2
Immunoglobulin G
2
zimberelimab
1
toripalimab
1
talimogene laherparepvec
1
silmitasertib
1
selinexor
1
ribociclib
1
peposertib
1
pemigatinib
1
olaratumab
1
olaparib
1
mirdametinib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
durvalumab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
Midazolam
×
1 year
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled